Veru (NASDAQ:VERU) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Veru (NASDAQ:VERUGet Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01, Zacks reports. Veru had a negative return on equity of 92.88% and a negative net margin of 223.85%.

Veru Price Performance

Shares of VERU traded up $0.02 on Friday, hitting $0.54. The company’s stock had a trading volume of 1,855,548 shares, compared to its average volume of 6,253,218. The company has a market capitalization of $79.24 million, a PE ratio of -1.93 and a beta of -0.54. Veru has a fifty-two week low of $0.40 and a fifty-two week high of $1.92. The company has a 50 day moving average price of $0.71 and a 200 day moving average price of $0.77.

Analysts Set New Price Targets

VERU has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of Veru in a research note on Thursday, January 2nd. Oppenheimer restated an “outperform” rating and set a $5.00 price target on shares of Veru in a research note on Tuesday, November 5th.

View Our Latest Analysis on VERU

About Veru

(Get Free Report)

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

Recommended Stories

Earnings History for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.